Cognitive evaluation of disease-modifying efficacy of donepezil in the APP23 mouse model for Alzheimer’s disease

Author： Van Dam Debby Coen Katrien De Deyn Peter

ISSN： 0033-3158

Source： Psychopharmacology, Vol.197, Iss.1, 2008-03, pp. : 37-43

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Related content

Protease inhibitors as potential disease-modifying therapeutics for Alzheimer’s disease

By Beher Dirk Graham Samuel L

Expert Opinion on Investigational Drugs, Vol. 14, Iss. 11, 2005-11 ,pp. : 1385-1409

Informa Healthcare

Access to resources Recommend Favorite

Effects of sub-chronic donepezil on brain Abeta and cognition in a mouse model of Alzheimer’s disease

By Easton Amy Sankaranarayanan Sethu Tanghe An Terwel Dick Lin Alan Hoque Nina Bourin Clotilde Gu Huidong Ahlijanian Michael Bristow Linda

Psychopharmacology, Vol. 230, Iss. 2, 2013-11 ,pp. : 279-289

Springer Publishing Company

Access to resources Recommend Favorite

The pharmacology of donepezil: a new treatment for Alzheimer’s disease

By Wilkinson D.G.

Expert Opinion on Pharmacotherapy, Vol. 1, Iss. 1, 1999-11 ,pp. : 121-135

Informa Healthcare

Access to resources Recommend Favorite

Donepezil: potential neuroprotective and disease-modifying effects

By Jacobson Sandra A Sabbagh Marwan N

Expert Opinion on Drug Metabolism and Toxicology, Vol. 4, Iss. 10, 2008-10 ,pp. : 1363-1369

Informa Healthcare

Access to resources Recommend Favorite

Efficacy and Safety of Donepezil in Patients with Alzheimers Disease: Results of a Global, Multinational, Clinical Experience Study

By Boada-Rovira M.

Drugs & Aging, Vol. 21, Iss. 1, 2004-01 ,pp. : 43-53

Adis International

Access to resources Recommend Favorite